Meningococcal vaccine development - from glycoconjugates against MenACWY to proteins against MenB - potential for broad protection against meningococcal disease

Vaccine

Volumn 30, Issue SUPPL. 2, 2012, Pages

  Dull, Peter M ^a   McIntosh, E David ^b  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^b Novartis Vaccines and Diagnostics   (Netherlands)

Author keywords

Meningitis; Meningococcal disease; Prevention; Vaccination

Indexed keywords

BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID CRM197; MENB VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; PORIN A; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNOGENICITY; MENINGOCOCCOSIS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; VACCINATION;

BIOMEDICAL RESEARCH; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; SEROTYPING; VACCINES, CONJUGATE; VACCINES, SUBUNIT;

EID: 84861120227     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.062     Document Type: Article

References (76)

1. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol 2000, 3(5):445-450.
2. Donnelly J., Medini D., Boccadifuoco G., Biolchi A., Ward J., Frasch C., et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010, 107(45):19490-19495.
3. Stephens D.S., Greenwood B., Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007, 369(9580):2196-2210.
4. Bilukha O.O., Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005, 54(RR-7):1-21.
5. SAGE Meningococcal vaccines: WHO position paper. Wkly Epidemiol Rec (WER) 2011, 47(86):521-540. http://www.who.int/wer.
6. Broker M., Dull P.M., Rappuoli R., Costantino P. Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. Vaccine 2009, 27(41):5574-5580.
7. Bilukha O., Messonnier N., Fischer M. Use of meningococcal vaccines in the United States. Pediatr Infect Dis J 2007, 26(5):371-376.
8. Rosenstein N., Levine O., Taylor J.P., Evans D., Plikaytis B.D., Wenger J.D., et al. Efficacy of meningococcal vaccine and barriers to vaccination. JAMA 1998, 279(6):435-439.
9. CDC.Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices Recommended adult immunization schedule-United States. MMWR Morb Mortal Wkly Rep 2009, 57(53).
10. Reingold A.L., Hightower A.W., Bolan G.A., Jones E.E., Tiendrebeogo H., Broome C.V., et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985, 2(July):114-118.
11. Granoff D.M., Gupta R.K., Belshe R.B., Anderson E.L. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998, 178(3):870-874.
12. Keyserling H., Papa T., Koranyi K., Ryall R., Bassily E., Bybel M.J., et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005, 159(10):907-913.
13. Richmond P., Kaczmarski E., Borrow R., Findlow J., Clark S., McCann R., et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000, 181(2):761-764.
14. Broker M., Veitch K. Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine. Travel Med Infect Dis 2010, 8(1):47-50.
15. MacDonald N.E., Halperin S.A., Law B.J., Forrest B., Danzig L.E., Granoff D.M. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 1998, 280(19):1685-1689.
16. Maiden M.C., Ibarz-Pavon A.B., Urwin R., Gray S.J., Andrews N.J., Clarke S.C., et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008, 197(5):737-743.
17. Rennels M., King J., Ryall R., Papa T., Froeschle J. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004, 23(5):429-435.
18. Bröker M., Costantino P., DeTora L., McIntosh E.D., Rappuoli R. Biochemical and biological characteristics of cross-reacting material 197 (CRM197), a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications. Biologicals 2011, 39(4):195-204.
19. Giannini G., Rappuoli R., Ratti G. The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Res 1984, 12(10):4063-4069.
20. Lagos R., Munoz A., Levine M.M., Watson W., Chang I., Paradiso P. Immunology of combining CRM(197) conjugates for Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae in Chilean infants. Vaccine 2009, 27(17):2299-2305.
21. Halperin S.A., McDonald J., Samson L., Danzig L., Santos G., Izu A., et al. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study. Clin Invest Med 2002, 25(6):243-251.
22. Huebner R.E., Nicol M., Mothupi R., Kayhty H., Mbelle N., Khomo E., et al. Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines. Vaccine 2004, 23(6):802-806.
23. MacLennan J.M., Shackley F., Heath P.T., Deeks J.J., Flamank C., Herbert M., et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA 2000, 283(21):2795-2801.
24. Bardotti A., Averani G., Berti F., Berti S., Galli C., Giannini S., et al. Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines against Neisseria meningitidis groups Y and W135. Vaccine 2005, 23(16):1887-1899.
25. Costantino P., Norelli F., Giannozzi A., D'Ascenzi S., Bartoloni A., Kaur S., et al. Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines. Vaccine 1999, 17(9-10):1251-1263.
26. Paoletti L.C., Wessels M.R., Michon F., DiFabio J., Jennings H.J., Kasper D.L. Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun 1992, 60(10):4009-4014.
27. Bardotti A., Averani G., Berti F., Berti S., Carinci V., D'Ascenzi S., et al. Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases. Vaccine 2008, 26(18):2284-2296.
28. Frasch C.E., Borrow R., Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009, 27(Suppl. 2):B112-B116.
29. Jackson L.A., Jacobson R.M., Reisinger K.S., Anemona A., Danzig L.E., Dull P.M. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J 2009, 28(2):86-91.
30. Snape M.D., Perrett K.P., Ford K.J., John T.M., Pace D., Yu L.M., et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008, 299(2):173-184.
31. Jackson L.A., Baxter R., Reisinger K., Karsten A., Shah J., Bedell L., et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009, 49(1):e1-e10.
32. ® among healthy adolescents. Hum Vaccin 2010, 6(11):881-887.
33. ® in adolescents enrolled in phase II and III clinical studies. 49th annual meeting of IDSA 2011.
34. Perrett K.P., Snape M.D., Ford K.J., John T.M., Yu L.M., Langley J.M., et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J 2009, 28(3):186-193.
35. Klein N.P., Reisinger K.S., Johnston W., Odrljin T., Gill C.J., Bedell L., et al. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J 2012, 31(1):64-71.
36. Froholm L.O., Berdal B.P., Bovre K., Gaustad P., Harboe A., Holten E., et al. Meningococcal group B vaccine trial in Norway 1981-1982. Preliminary report of results available November 1982. NIPH Ann 1983, 6(2):133-138.
37. Rosenqvist E., Harthug S., Froholm L.O., Hoiby E.A., Bovre K., Zollinger W.D. Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection. J Clin Microbiol 1988, 26(8):1543-1548.
38. Finne J., Bitter-Suermann D., Goridis C., Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987, 138(12):4402-4407.
39. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983, 2(8346):355-357.
40. Hayrinen J., Jennings H., Raff H.V., Rougon G., Hanai N., Gerardy-Schahn R., et al. Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J Infect Dis 1995, 171(6):1481-1490.
41. Bai X., Findlow J., Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther 2011, 11(7):969-985.
42. Updated recommendations for use of meningococcal conjugate vaccines-Advisory Committee on Immunization Practices (ACIP). MMWR 2010, 60(03):72-76.
43. European Centre for Disease Prevention and Control Surveillance of invasive bacterial diseases in Europe 2008/2009 2011, ECDC, Stockholm.
44. Bjune G., Gronnesby J.K., Hoiby E.A., Closs O., Nokleby H. Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Ann 1991, 14(2):125-130. discussion 30-2.
45. Taha M.K., Zarantonelli M.L., Alonso J.M., Naess L.M., Holst J., Feiring B., et al. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. Vaccine 2007, 25(14):2537-2538.
46. Rodriguez A.P., Dickinson F., Baly A., Martinez R. The epidemiological impact of antimeningococcal B vaccination in Cuba. Mem Inst Oswaldo Cruz 1999, 94(4):433-440.
47. de Moraes J.C., Perkins B.A., Camargo M.C., Hidalgo N.T., Barbosa H.A., Sacchi C.T., et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992, 340(8827):1074-1078.
48. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005, 23(17-18):2191-2196.
49. Sacchi C.T., Whitney A.M., Popovic T., Beall D.S., Reeves M.W., Plikaytis B.D., et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J Infect Dis 2000, 182(4):1169-1176.
50. Galloway Y., Stehr-Green P., McNicholas A., O'Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009, 38(2):413-418.
51. Oster P., O'Hallahan J., Aaberge I., Tilman S., Ypma E., Martin D. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine 2007, 25(16):3075-3079.
52. Granoff D.M. Review of meningococcal Group B vaccines. Clin Infect Dis 2010, 50(Suppl. 2):S54-S65.
53. Keiser P.B., Biggs-Cicatelli S., Moran E.E., Schmiel D.H., Pinto V.B., Burden R.F., et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 2011, 29:1413-1420.
54. Boutriau D., Poolman J., Borrow R., Findlow J., Domingo J.D., Puig-Barbera J., et al. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin Vaccine Immunol 2007, 14(1):65-73.
55. de Kleijn E.D., de Groot R., Labadie J., Lafeber A.B., van den Dobbelsteen G., van Alphen L., et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 2000, 18(15):1456-1466.
56. van den Dobbelsteen G.P., van Dijken H.H., Pillai S., van Alphen L. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine 2007, 25(13):2491-2496.
57. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Aricò B., Comanducci M., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287(5459):1816-1820.
58. Madico G., Welsch J.A., Lewis L.A., McNaughton A., Perlman D.H., Costello C.E., et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006, 177(1):501-510.
59. Schneider M.C., Exley R.M., Chan H., Feavers I., Kang Y.H., Sim R.B., et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 2006, 176(12):7566-7575.
60. Comanducci M., Bambini S., Brunelli B., Adu-Bobie J., Arico B., Capecchi B., et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002, 195(11):1445-1454.
61. Capecchi B., Adu-Bobie J., Di Marcello F., Ciucchi L., Masignani V., Taddei A., et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 2005, 55(3):687-698.
62. Mazzon C., Baldani-Guerra B., Cecchini P., Kasic T., Viola A., de Bernard M., et al. IFN-gamma and R-848 dependent activation of human monocyte-derived dendritic cells by Neisseria meningitidis adhesin A. J Immunol 2007, 179(6):3904-3916.
63. Plested J.S., Granoff D.M. Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B. Clin Vaccine Immunol 2008, 15(5):799-804.
64. Serruto D., Rappuoli R., Scarselli M., Gros P., van Strijp J.A. Molecular mechanisms of complement evasion: learning from staphylococci and meningococci. Nat Rev Microbiol 2010, 8(6):393-399.
65. Welsch J.A., Moe G.R., Rossi R., Adu-Bobie J., Rappuoli R., Granoff D.M. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 2003, 188(11):1730-1740.
66. Holst J., Martin D., Arnold R., Huergo C.C., Oster P., O'Hallahan J., et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27(Suppl. 2):B3-B12.
67. Findlow J., Borrow R., Snape M.D., Dawson T., Holland A., John T.M., et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without Outer Membrane Vesicles, administered in infancy. Clin Infect Dis 2010, 51(10):1127-1137.
68. Snape M.D., Dawson T., Oster P., Evans A., John T.M., Ohene-Kena B., et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010, 29(11):e71-e79.
69. Vesikari T., Esposito S., Kimura A., Kleinschmidt A., Ypma E., Toneatto D., et al. Immunogenicity of an investigational multicomponent meningococcal serogroup B vaccine in healthy infants at 2, 4 and 6 months of age. 17th international pathogenic Neisseria conference (IPNC) 2010, Abstract P180.
70. Vesikari T., Prymula R., Liese J., Kollaritsch H., Bona G., Kimura A., et al. Booster dose at 12 months of an investigational meningococcal serogroup B vaccine (4CMenB) in toddlers previously primed at 2, 4, 6 months. 29th annual ESPID conference 2011, Abstract 877.
71. Kimura A., Toneatto D., Kleinschmidt A., Wang H., Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol 2011, 18(3):483-486.
72. Santolaya M.E., O'Ryan M., Valenzuela M.T., Prado V., Vergara R., Muñoz A., et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase IIb/III randomised, observer-blind, placebo-controlled study. Lancet 2012, 379. 10.1016/S0140-6736(11)61713-3.
73. Donnelly J, Medina D, Giuliani M, Boccadifuoco G, Stella M, Frosi G, et al. Estimating the potential strain coverage in Europe of a multicomponent vaccine targeting serogroup B meningococci. Poster presented at the 11th annual meeting of the European Meningococcal Disease Society (EMGM); 2011.
74. Novartis A phase 2b/3, multi-center, extension study of V72P10 to assess antibody persistence at eighteen months after the completion of the vaccination course in study V72P10. http://clinicaltrialsgov/show/NCT01148524.
75. Novartis A phase 3 observer blind randomized, multi-center, controlled study to evaluate the effect of Novartis Vaccine's meningococcal B recombinant and MenACWY conjugate vaccines on pharyngeal carriage of N. meningitidis in young adults. http://clinicaltrialsgov/show/NCT01214850.
76. Novartis A phase 3, open-label, multi-center, extension study of V72P13E1 to assess antibody persistence at one year after a fourth dose boost or two catch-up doses of Novartis meningococcal B recombinant vaccine administered starting at 12 months of age and to evaluate the response to a third dose boost or two catch-up doses starting at 24 months of age. http://clinicaltrialsgov/show/NCT01139021.